Contact Us FAQ´s Technology Services About Us Home
 
 
 
 
Services
 
High-Throughput Absorption Depth Profiling in Stratum Corneum

High-Throughput Corneal/Scleral Absorption and Pentration Screening

High-Throughput In Vitro Release Testing (HT-IVRT)

High-Throughput Nail Penetration Screening

High-Throughput Screening of Compound Library for Topical and Transdermal Delivery

High-Throughput Skin Absorption and Penetration Screening

In Vitro Skin Barrier Integrity and Skin Irritation/Corrosion Test

Ophthalmic Formulation Development and Optimization

Preformulation, design, Development, and Screening

Skin Absorption and Penetration Enhancement and Retardation Development

Topical Formulation Development And Optimization

News & Events
High-Throughput Formulation Screening Service for Topical and Transdermal Drug Development 07-16-2010
Chicago, IL, U.S.A, July 26, 2010 – Zyleris PharmaTech (www.Zyleris.com) has announced today the launch of its high-throughput formulation screening service for topical and transdermal drug development based on the company’s innovative experimentation technology.

Zyleris’ technology is designed to transform topical and transdermal drug development.  The technology utilizes Franz Cell principle in a high-throughput fashion, which is at least 20x faster than present industrial standard Franz Cell technology and lowering costs up to 90% per formulation.  It also offers higher detection sensitivity than Franz Cell technology due to its unique design.  The main technical features include easy-to-use compact design, flexible diffusion area suitable for percutaneous absorption and permeation studies, all glass and Teflon construction, and an easy sample collection mechanism.

"Many researchers tell us that identifying suitable topical and transdermal formulations for clinical development is often quite tedious and expensive.  Due to the limitations of current Franz Cell technology, such as low speed and high cost, only a limited number of candidate formulations can reasonably be screened and evaluated.  Researchers always wonder: is the formulation slated for clinical development really best possible one to move forward?  Thus, the market is ripe for a high speed and yet cost efficient solution.  Our technology fills this gap by offering the best of both worlds - speed associated with high-throughput technology and yet result compatibility with industrial standard Franz Cell technology.  We understood that from the beginning and developed a truly innovative solution for this challenge and brought speed and cost efficiency to the process." says Zyleris founder and CEO, Jerry Zhang, PhD.

Zyleris’ objective is to continue developing innovative solutions, technologies, and services for topical and transdermal drug research and development.

About Zyleris PharmaTech

Founded in 2009 and headquartered in Chicago, IL, U.S.A, Zyleris PharmaTech is a contract research service company delivering best-in-class high-throughput experimentation technologies and services for accelerating topical and transdermal drug R&D process.  For more information about the company, visit www.zyleris.com.

Contact Information

Jerry Zhang

Phone: 847-604-8474

High-Throughput Screening of Compound Library for Topical and Transdermal Delivery 04-27-2011
Zyleris PharmaTech (www.Zyleris.com) has announced the launch of a new drug development service: high-throughput screening of compound library to identify drug candidates for topical and transdermal delivery.

The screening service utilizes Zyleris’ Franz Cell-based high-throughput technology.  Each screening system consists of a compact 108-cell screening station with flexibility for both absorption and penetration studies.  The system is fully validated against industry-standard Franz Cell technology.  It can be used with any human or animal tissue including skin, buccal, lung, ocular, nail (with adapter) or synthetic membrane. 

For many local and system indications, topical and transdermal delivery is a valuable and often preferred option in the drug development process.  However, current Franz Cell technology is ill-equipped for screening of compound library.  The market is ripe for a high speed and yet cost efficient solution.  Our system fills this gap.  It will allow researchers to rapidly screen compound library and make informed, go/no-go decision with respect to the delivery route.

Zyleris’ objective is to continue developing innovative solutions, technologies, and services for topical and transdermal drug research and development.

About Zyleris PharmaTech

Founded in 2009 and headquartered in Chicago, IL, U.S.A, Zyleris PharmaTech is a contract research service company delivering best-in-class high-throughput experimentation technologies and services for accelerating topical and transdermal drug R&D process.  For more information about the company, please visit us at www.zyleris.com.